Tissue-specific regulatory T cells: biomarker for acute graft-vs-host disease and survival.

[1]  S. Ziegler,et al.  Blood and gastric FOXP3+ T cells are not decreased in human gastric graft-versus-host disease. , 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[2]  R. Storb,et al.  Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. , 2011, Blood.

[3]  J. Crowe,et al.  Regulatory T cell expression of CLA or α4β7 and skin or gut acute GVHD outcomes , 2011, Bone Marrow Transplantation.

[4]  D. Campbell,et al.  Phenotypical and functional specialization of FOXP3+ regulatory T cells , 2011, Nature Reviews Immunology.

[5]  J. Ritz,et al.  Up-Regulation of alpha4beta7 integrin on peripheral T cell subsets correlates with the development of acute intestinal graft-versus-host disease following allogeneic stem cell transplantation. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[6]  D. Massi,et al.  Increase in FOXP3+ regulatory T cells in GVHD skin biopsies is associated with lower disease severity and treatment response. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[7]  M. Pasquini,et al.  Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network. , 2009, Blood.

[8]  R. Jessberger,et al.  Regulatory T cells sequentially migrate from inflamed tissues to draining lymph nodes to suppress the alloimmune response. , 2009, Immunity.

[9]  C. Contag,et al.  In vivo dynamics of regulatory T-cell trafficking and survival predict effective strategies to control graft-versus-host disease following allogeneic transplantation. , 2007, Blood.

[10]  E. Shevach.  From vanilla to 28 flavors: multiple varieties of T regulatory cells. , 2006, Immunity.

[11]  Chang H. Kim.  Migration and function of FoxP3+ regulatory T cells in the hematolymphoid system. , 2006, Experimental hematology.

[12]  E. Thiel,et al.  Mucosal FOXP3+ regulatory T cells are numerically deficient in acute and chronic GvHD. , 2006, Blood.

[13]  B. Blazar,et al.  Acute graft-versus-host disease: from the bench to the bedside. , 2005, Blood.

[14]  E. Hauben,et al.  Utilizing regulatory T cells to control alloreactivity. , 2005, Cytotherapy.

[15]  B. Salomon,et al.  Therapeutic potential of CD4+ CD25+ regulatory T cells in allogeneic transplantation. , 2005, Cytotherapy.

[16]  Matthias Edinger,et al.  Only the CD62L+ subpopulation of CD4+CD25+ regulatory T cells protects from lethal acute GVHD. , 2005, Blood.

[17]  J. Serody,et al.  L-Selectin(hi) but not the L-selectin(lo) CD4+25+ T-regulatory cells are potent inhibitors of GVHD and BM graft rejection. , 2004, Blood.

[18]  C. Thoburn,et al.  Association of Foxp3 regulatory gene expression with graft-versus-host disease. , 2004, Blood.

[19]  H. Deeg,et al.  Increasingly frequent diagnosis of acute gastrointestinal graft-versus-host disease after allogeneic hematopoietic cell transplantation. , 2004, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[20]  Linda A. Lee,et al.  Pathogenesis and treatment of graft-versus-host disease after bone marrow transplant. , 2003, Annual review of medicine.

[21]  A. Rudensky,et al.  Foxp3 programs the development and function of CD4+CD25+ regulatory T cells , 2003, Nature Immunology.

[22]  S. Hori,et al.  Supporting Online Material , 2002 .

[23]  B. Blazar,et al.  The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality. , 2002, Blood.

[24]  G. Vogelsang,et al.  Management of graft-versus-host disease. , 2000, Blood reviews.

[25]  M. Toda,et al.  Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. , 1995, Journal of immunology.

[26]  E D Thomas,et al.  1994 Consensus Conference on Acute GVHD Grading. , 1995, Bone marrow transplantation.

[27]  A. Nademanee,et al.  Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease. , 1993, The New England journal of medicine.

[28]  R. Storb,et al.  A retrospective analysis of therapy for acute graft-versus-host disease: secondary treatment. , 1990, Blood.

[29]  J. Crowe,et al.  Homing in on acute graft vs. host disease: tissue-specific T regulatory and Th17 cells. , 2010, Current topics in microbiology and immunology.